Dr. Radich on Treatment Discontinuation in CML Off Trial

Jerald P. Radich, MD
Published: Thursday, Sep 27, 2018



Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses treatment discontinuation off trial for patients with chronic myeloid leukemia (CML).

About 50% of patients who reach a deep molecular response for several years are able to discontinue therapy and stay free of disease for about 2 to 3 years, says Radich.

It is strongly recommended that this is done solely on a clinical trial, says Radich, but the NCCN recognizes that physicians may attempt to do this off of a clinical trial, so guidelines have been put into place for physicians to follow. Radich explains that a patient has to be on drug for at least 2 years and have a documented deep response for more than 2 years; they cannot show up in the clinic one day with a good partial complete response.

After discontinuation, patients must be monitored every month for 6 months. Because of all these criteria, only a small percentage of patients should attempt to be discontinued off a clinical trial, concludes Radich.


Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses treatment discontinuation off trial for patients with chronic myeloid leukemia (CML).

About 50% of patients who reach a deep molecular response for several years are able to discontinue therapy and stay free of disease for about 2 to 3 years, says Radich.

It is strongly recommended that this is done solely on a clinical trial, says Radich, but the NCCN recognizes that physicians may attempt to do this off of a clinical trial, so guidelines have been put into place for physicians to follow. Radich explains that a patient has to be on drug for at least 2 years and have a documented deep response for more than 2 years; they cannot show up in the clinic one day with a good partial complete response.

After discontinuation, patients must be monitored every month for 6 months. Because of all these criteria, only a small percentage of patients should attempt to be discontinued off a clinical trial, concludes Radich.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x